Michael W. Freeman serves as an Equity Research Analyst at Raymond James, where he focuses on the Healthcare and Biotechnology sectors. In this role, he is recognized as "TopGun-Ranked." Prior to his current position, Freeman was an Equity Research Associate at Paradigm Capital, also specializing in Healthcare and Biotechnology.

His career history also includes experience as a Science Journalist and Editor at University Health Network.